LBRX Cash from 2010 to 2026
| LBRX Stock | 23.86 2.69 12.71% |
Cash | First Reported 2010-12-31 | Previous Quarter 26.4 M | Current Value 21.8 M | Quarterly Volatility 2.1 M |
Check LB Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LB Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 800, Net Interest Income of 2.1 M or Interest Income of 2.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. LBRX financial statements analysis is a perfect complement when working with LB Pharmaceuticals Valuation or Volatility modules.
LBRX | Cash | Build AI portfolio with LBRX Stock |
The evolution of Cash for LB Pharmaceuticals Common provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how LB Pharmaceuticals compares to historical norms and industry peers.
Latest LB Pharmaceuticals' Cash Growth Pattern
Below is the plot of the Cash of LB Pharmaceuticals Common over the last few years. Cash refers to the most liquid asset of LB Pharmaceuticals Common, which is listed under current asset account on LB Pharmaceuticals Common balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from LB Pharmaceuticals customers. The amounts must be unrestricted with restricted cash listed in a different LB Pharmaceuticals account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. LB Pharmaceuticals' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LB Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Cash | 10 Years Trend |
|
Cash |
| Timeline |
LBRX Cash Regression Statistics
| Arithmetic Mean | 21,435,259 | |
| Geometric Mean | 21,330,484 | |
| Coefficient Of Variation | 9.69 | |
| Mean Deviation | 807,367 | |
| Median | 21,404,000 | |
| Standard Deviation | 2,077,856 | |
| Sample Variance | 4.3T | |
| Range | 11.4M | |
| R-Value | 0.09 | |
| Mean Square Error | 4.6T | |
| R-Squared | 0.01 | |
| Significance | 0.73 | |
| Slope | 37,641 | |
| Total Sum of Squares | 69.1T |
LBRX Cash History
Other Fundumenentals of LB Pharmaceuticals Common
LB Pharmaceuticals Cash component correlations
Click cells to compare fundamentals
About LB Pharmaceuticals Financial Statements
LB Pharmaceuticals investors use historical fundamental indicators, such as LB Pharmaceuticals' Cash, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in LB Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Cash | 26.4 M | 21.8 M | |
| Cash And Short Term Investments | 32.2 M | 34 M | |
| Change In Cash | 7.6 M | 6 M | |
| Free Cash Flow | -48.4 M | -46 M | |
| Begin Period Cash Flow | 17.2 M | 13.7 M | |
| Total Cashflows From Investing Activities | 26.7 M | 28.1 M | |
| Other Cashflows From Financing Activities | 44.1 M | 25.4 M | |
| Other Non Cash Items | 3.1 M | 2.6 M | |
| Total Cash From Operating Activities | -47.7 M | -45.4 M | |
| Total Cash From Financing Activities | 44.1 M | 34.8 M | |
| End Period Cash Flow | 27 M | 21.9 M | |
| Free Cash Flow Yield | (1.01) | (0.96) | |
| Operating Cash Flow Per Share | (17.24) | (16.37) | |
| Free Cash Flow Per Share | (17.49) | (16.61) | |
| Cash Per Share | 7.12 | 6.98 | |
| Capex To Operating Cash Flow | (0.02) | (0.02) | |
| EV To Operating Cash Flow | (0.71) | (0.75) | |
| EV To Free Cash Flow | (0.70) | (0.74) | |
| Price To Operating Cash Flows Ratio | (1.04) | (1.09) | |
| Price To Free Cash Flows Ratio | (1.02) | (1.08) | |
| Cash Ratio | 3.26 | 3.10 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.91 | 0.81 | |
| Cash Flow Coverage Ratios | (16.48) | (15.65) | |
| Price Cash Flow Ratio | (1.04) | (1.09) | |
| Cash Flow To Debt Ratio | (16.48) | (15.65) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for LBRX Stock Analysis
When running LB Pharmaceuticals' price analysis, check to measure LB Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LB Pharmaceuticals is operating at the current time. Most of LB Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of LB Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LB Pharmaceuticals' price. Additionally, you may evaluate how the addition of LB Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.